lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

1 row where filing_uuid = "f83bf0bd-928d-4e49-927b-e05121aee3ed" and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: received_date (date)

issue_code 1

filing_year 1

filing_period 1

id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2264246 JOHNSON MATTHEY INC. f83bf0bd-928d-4e49-927b-e05121aee3ed Q1 JOHNSON MATTHEY INC. 401104441 JOHNSON MATTHEY INC. 2019 first_quarter PHA H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers. Commerce, Dept of (DOC),Environmental Protection Agency (EPA),Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2019-04-11T15:28:59.737000-04:00

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options: 

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);